IP Library › Granted Patent US 8,454,966
Granted Patent B2
US 8,454,966 · App. 12/807,084 · Granted Jun 4, 2013

Nanoparticles for protein drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,454,966
App. No.
12/807,084
Granted
Jun 4, 2013
Kind
B2
Abstract

The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Claims (18)

1. A pharmaceutical composition of nanoparticles for vaccine delivery comprising:

(a) a vaccine,

(b) a low molecular weight chitosan, and

(c) a polyglutamic acid or salt thereof, wherein said nanoparticles have a net positively charged surface.

2. The pharmaceutical composition of claim 1 , wherein said polyglutamic acid is γ-polyglutamic acid (γ-PGA) or α-polyglutamic acid (α-PGA).

3. The pharmaceutical composition of claim 1 , wherein said nanoparticles are further encapsulated in a capsule.

4. The pharmaceutical composition of claim 1 , wherein the low molecular weight chitosan has a molecular weight of 80 kDa.

5. The pharmaceutical composition of claim 1 , wherein the low molecular weight chitosan has a molecular weight of 40 kDa.

6. The pharmaceutical composition of claim 1 , wherein the low molecular weight chitosan is trimethyl chitosan, N,O-carboxylmethyl chitosan, or chitosan modified with a side chain selected from the group consisting of alkyl group and polyethylene glycol.

7. The pharmaceutical composition of claim 1 , wherein the composition is in a tablet form with one or more excipients.

8. The pharmaceutical composition of claim 1 , wherein said vaccine is a prophylactic vaccine.

9. The pharmaceutical composition of claim 1 , wherein said vaccine is a therapeutic vaccine.

10. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral administration.

11. The pharmaceutical composition of claim 1 , wherein the composition is formulated for parenteral administration.

12. The pharmaceutical composition of claim 1 , wherein said nanoparticles are prepared via a simple and mild ionic-gelation method.

13. The pharmaceutical composition of claim 1 , wherein said nanoparticles are crosslinked with a crosslinking agent or with infrared irradiation.

14. The pharmaceutical composition of claim 13 , wherein a degree of crosslinking of said nanoparticles is less than 50%.

15. The pharmaceutical composition of claim 13 , wherein a degree of crosslinking of said nanoparticles is ranged between 1% and 20%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2016
From: GP MEDICAL, INC
To: NANOMEGA MEDICAL CORPORATION
Reel/Frame 038382/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2011
From: SUNG, HSING-WEN; LIN, YU-HSIN; LIANG, HSIANG-FA; TU, HOSHENG
To: GP MEDICAL, INC.
Reel/Frame 025861/0589 →